Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Summary

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Timeline

Start

2014-02-11

Primary completion

2016-02-11

Completion

2016-06-21

Outcome

Missed primary endpoint

Stopped: “The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.”

registry p = 0.7562; Hazard Ratio (HR) 0.877 (80% CI 0.509 to 1.51); Log Rank NCT02119650 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	15 mg	Oral
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Indications